Session Information
The INOVATe Study (Individualised Ovarian Cancer Treatment Through Integration of Genomic Pathology into Multidisciplinary Care), is a major precision oncology program that has enrolled over 750 women in NSW since 2016. The goal is to facilitate recruitment to Phase I/II clinical trials of targeted cancer treatments through multi-modal molecular testing. In this Molecular Tumour Board session, members of the INOVATe team will provide an overview of the program and present some illustrative cases.

Professor Anna DeFazio, Director Sydney Cancer Partners; Sydney West Chair of Translational Cancer Research, The University of Sydney
Clinical Associate Professor Rosemary Balleine, Clinical and Strategic Partnerships Lead, Sydney Cancer Partners
Dr Cristina Mapagu, Medical Oncologist, ISLHD; Clinical Research Fellow, INOVATe

Related Education & Resources